These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 15761697

  • 1. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
    Millan MJ.
    Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697
    [Abstract] [Full Text] [Related]

  • 2. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.
    Millan MJ.
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):191-213. PubMed ID: 12769627
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P, Dubroqua S, Yee BK.
    Curr Pharm Des; 2015 Apr; 21(26):3771-87. PubMed ID: 26205290
    [Abstract] [Full Text] [Related]

  • 4. Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat.
    Chiusaroli R, Garofalo P, Espinoza S, Neri E, Caselli G, Lanza M.
    Pharmacol Res; 2010 May; 61(5):430-6. PubMed ID: 20045056
    [Abstract] [Full Text] [Related]

  • 5. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J, Chaki S, Hikichi H.
    Behav Brain Res; 2015 Feb 01; 278():186-92. PubMed ID: 25300471
    [Abstract] [Full Text] [Related]

  • 6. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC.
    Int Rev Neurobiol; 2007 Feb 01; 78():69-108. PubMed ID: 17349858
    [Abstract] [Full Text] [Related]

  • 7. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR, Svensson KA.
    Pharmacol Ther; 2008 Dec 01; 120(3):317-32. PubMed ID: 18805436
    [Abstract] [Full Text] [Related]

  • 8. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M, Nagel J, Gravius A, Schäfer D, Danysz W.
    Amino Acids; 2007 Feb 01; 32(2):173-8. PubMed ID: 16699816
    [Abstract] [Full Text] [Related]

  • 9. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT.
    Am J Psychiatry; 1999 Nov 01; 156(11):1822-5. PubMed ID: 10553752
    [Abstract] [Full Text] [Related]

  • 10. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov 01; 30(5-6):201-6. PubMed ID: 21226316
    [Abstract] [Full Text] [Related]

  • 11. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS, Hammonds MD, Kee BS.
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb 01; 258(1):16-27. PubMed ID: 17901997
    [Abstract] [Full Text] [Related]

  • 12. Treatment of negative and cognitive symptoms.
    Javitt DC.
    Curr Psychiatry Rep; 1999 Oct 01; 1(1):25-30. PubMed ID: 11122902
    [Abstract] [Full Text] [Related]

  • 13. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG.
    Curr Top Med Chem; 2006 Oct 01; 6(8):771-85. PubMed ID: 16719816
    [Abstract] [Full Text] [Related]

  • 14. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.
    Lipina T, Labrie V, Weiner I, Roder J.
    Psychopharmacology (Berl); 2005 Apr 01; 179(1):54-67. PubMed ID: 15759151
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
    Chaki S, Shimazaki T, Karasawa J, Aoki T, Kaku A, Iijima M, Kambe D, Yamamoto S, Kawakita Y, Shibata T, Abe K, Okubo T, Sekiguchi Y, Okuyama S.
    Psychopharmacology (Berl); 2015 Aug 01; 232(15):2849-61. PubMed ID: 25869273
    [Abstract] [Full Text] [Related]

  • 16. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
    Coyle JT.
    Neurotox Res; 2006 Dec 01; 10(3-4):221-33. PubMed ID: 17197372
    [Abstract] [Full Text] [Related]

  • 17. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
    Heresco-Levy U, Javitt DC.
    Schizophr Res; 2004 Feb 01; 66(2-3):89-96. PubMed ID: 15061240
    [Abstract] [Full Text] [Related]

  • 18. Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics.
    Bennett S, Gronier B.
    Eur J Pharmacol; 2005 Dec 19; 527(1-3):52-9. PubMed ID: 16307739
    [Abstract] [Full Text] [Related]

  • 19. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats.
    Shimazaki T, Kaku A, Chaki S.
    Psychopharmacology (Berl); 2010 Apr 19; 209(3):263-70. PubMed ID: 20198471
    [Abstract] [Full Text] [Related]

  • 20. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K.
    Expert Opin Ther Targets; 2014 Sep 19; 18(9):1049-63. PubMed ID: 24965576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.